PHOSPHODIESTERASE TYPE 5 INHIBITOR RELEASING NITROGEN OXIDE Russian patent published in 2022 - IPC C07D403/14 C07D487/04 A61K31/21 A61K31/506 A61K31/519 A61P27/06 A61P27/02 

FIELD: medicine.

SUBSTANCE: invention relates to a compound of the formula (I) or (II), or its stereoisomer, or pharmaceutically acceptable salt, where R₁ is a residue of a molecule releasing nitrogen oxide, having the following formula: -C(O)-(O-CH₂)_y(CH₂)_m-[O-(CH₂)_n]_p-(CH-ONO₂)_q-CH₂-ONO₂, where y is equal to 1 or 0; p is equal to 1 or 0; q is equal to 1 or 0; mis equal to an integer from 1 to 10; n is equal to an integer from 1 to 6; R₂ is ethyl or n-propyl; R₃ is methyl or ethyl; provided that, when, in the formula (I), R₂ is ethyl, then R₃ is methyl, or, when R₂ is n-propyl, then R₃ is ethyl. The invention also relates to an ophthalmic composition having activity of a phosphodiesterase type 5 (PDE5) inhibitor, based on the compound of the formula (I) or (II).

EFFECT: new compounds and an ophthalmic composition based on them are obtained, which can be used in medicine for the treatment of an eye condition associated with increased intraocular pressure, such as eye hypertension, glaucoma, or retinopathy.

17 cl, 7 tbl, 31 ex